Autoantibody signatures discovered by HuProt protein microarray to enhance the diagnosis of lung cancer

Copyright © 2022 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 246(2023) vom: 20. Jan., Seite 109206
1. Verfasser: Wang, Yulin (VerfasserIn)
Weitere Verfasser: Li, Jiaqi, Zhang, Xue, Liu, Man, Ji, Longtao, Yang, Ting, Wang, Kaijuan, Song, Chunhua, Wang, Peng, Ye, Hua, Shi, Jianxiang, Dai, Liping
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Autoantibodies Diagnostic model HuProt protein microarray Lung cancer Biomarkers, Tumor Antigens, Neoplasm
LEADER 01000naa a22002652 4500
001 NLM350400857
003 DE-627
005 20231226044912.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2022.109206  |2 doi 
028 5 2 |a pubmed24n1167.xml 
035 |a (DE-627)NLM350400857 
035 |a (NLM)36528251 
035 |a (PII)S1521-6616(22)00287-X 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Wang, Yulin  |e verfasserin  |4 aut 
245 1 0 |a Autoantibody signatures discovered by HuProt protein microarray to enhance the diagnosis of lung cancer 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 17.01.2023 
500 |a Date Revised 12.02.2023 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2022 Elsevier Inc. All rights reserved. 
520 |a This study aims to discover novel autoantibodies against tumor-associated antigens (TAAs) and establish diagnostic models for assisting in the diagnosis of lung cancer and discrimination of pulmonary nodules (PNs). Ten autoantibodies to TAAbs (TAAbs) were discovered by means of protein microarray and their serum level was also higher in 212 LC patients than that in 212 NC of validation cohort 1 (P < 0.05). The model 1 comprising 4 TAAbs and CEA reached an AUC of 0.813 (95%CI: 0.762-0.864) for diagnosing LC from normal individuals. Five TAAbs existed a significant difference between 105 malignant pulmonary nodules (MPNs) and 105 benign pulmonary nodules (BPNs) patients in validation cohort 2 (P < 0.05). Model 2 could distinguish MPNs from BPNs with an AUC of 0.845. High-throughput protein microarray is an efficient approach in discovering novel TAAbs which could be used as biomarkers in lung cancer diagnosis 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Autoantibodies 
650 4 |a Diagnostic model 
650 4 |a HuProt protein microarray 
650 4 |a Lung cancer 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a Biomarkers, Tumor  |2 NLM 
650 7 |a Antigens, Neoplasm  |2 NLM 
700 1 |a Li, Jiaqi  |e verfasserin  |4 aut 
700 1 |a Zhang, Xue  |e verfasserin  |4 aut 
700 1 |a Liu, Man  |e verfasserin  |4 aut 
700 1 |a Ji, Longtao  |e verfasserin  |4 aut 
700 1 |a Yang, Ting  |e verfasserin  |4 aut 
700 1 |a Wang, Kaijuan  |e verfasserin  |4 aut 
700 1 |a Song, Chunhua  |e verfasserin  |4 aut 
700 1 |a Wang, Peng  |e verfasserin  |4 aut 
700 1 |a Ye, Hua  |e verfasserin  |4 aut 
700 1 |a Shi, Jianxiang  |e verfasserin  |4 aut 
700 1 |a Dai, Liping  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 246(2023) vom: 20. Jan., Seite 109206  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:246  |g year:2023  |g day:20  |g month:01  |g pages:109206 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2022.109206  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 246  |j 2023  |b 20  |c 01  |h 109206